{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:07:53Z","timestamp":1789150073725,"version":"build-2803163510"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12870"],"award-info":[{"award-number":["25K12870"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    This retrospective study compared the short-term efficacy of a two-dose intravitreal aflibercept (IVA) 8-mg loading regimen (2024\u20132025) with a conventional three-dose IVA 2-mg regimen (2013\u20132014) for treatment-na\u00efve neovascular age-related macular degeneration (nAMD). Using 1:1 propensity score matching for age, sex, nAMD subtype, and baseline visual acuity, we evaluated 31 eyes per group. The primary endpoint was the proportion of eyes achieving a fluid-free center subfield one month after completing the respective loading phase (at 2 and 3 months from baseline, respectively). The fluid-free proportion was numerically higher in the 8-mg group (90.3%; 95% confidence interval [CI], 74.2\u201398.0%) than in the 2-mg group (80.6%; 95% CI, 62.5\u201392.5%); however, the difference was not statistically significant (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.28). Both regimens yielded significant reductions in central retinal thickness, central choroidal thickness, and pigment epithelial detachment height, with no significant between-group differences. Within the 8-mg group, baseline intraretinal fluid strongly correlated with one-month visual acuity (r\u2009=\u20090.61,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). These exploratory findings suggest that a reduced two-dose aflibercept 8-mg loading regimen provided short-term anatomical outcomes that did not differ significantly from the standard three-dose 2-mg regimen. This shortened loading phase potentially reduces the initial treatment burden. Further prospective studies should validate these preliminary outcomes.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0349947","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:25:31Z","timestamp":1789147531000},"page":"e0349947","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-na\u00efve neovascular age-related macular degeneration"],"prefix":"10.1371","volume":"21","author":[{"given":"Mai","family":"Shirakami","sequence":"first","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7574-1749","authenticated-orcid":true,"given":"Manabu","family":"Miyata","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hata","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tsukui","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ueda-Arakawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Miyake","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kadomoto","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3196-6604","authenticated-orcid":true,"given":"Yuki","family":"Muraoka","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine","place":["Kyoto City, Kyoto Prefecture, Japan"],"department":["Department of Ophthalmology and Visual Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"9","key":"pone.0349947.ref001","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"U Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0349947.ref002","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"WL Wong","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"1","key":"pone.0349947.ref003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology","volume":"126","author":"SJ Bakri","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"pone.0349947.ref004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10384-022-00969-2","article-title":"Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan","volume":"67","author":"Y Hashimoto","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"pone.0349947.ref005","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00417-023-05982-w","article-title":"Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration","volume":"261","author":"Y Hama","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"pone.0349947.ref006","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1007\/s12325-020-01298-x","article-title":"Efficacy and treatment burden of intravitreal aflibercept versus intravitreal ranibizumab treat-and-extend regimens at 2 years: Network meta-analysis incorporating individual patient data meta-regression and matching-adjusted indirect comparison","volume":"37","author":"M Ohji","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"pone.0349947.ref007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review","volume":"128","author":"M Okada","year":"2021","journal-title":"Ophthalmology"},{"issue":"10432","key":"pone.0349947.ref008","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"P Lanzetta","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"pone.0349947.ref009","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","article-title":"Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study","volume":"259","author":"M Ohji","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"pone.0349947.ref010","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"JS Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"pone.0349947.ref011","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524096","article-title":"Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials","volume":"245","author":"C Regillo","year":"2022","journal-title":"Ophthalmologica"},{"key":"pone.0349947.ref012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2016.12.006","article-title":"Insights Into Epiretinal Membranes: Presence of Ectopic Inner Foveal Layers and a New Optical Coherence Tomography Staging Scheme","volume":"175","author":"A Govetto","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"pone.0349947.ref013","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"AS Willoughby","year":"2015","journal-title":"Ophthalmology"},{"key":"pone.0349947.ref014","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial","author":"JF Korobelnik","year":"2025","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0349947.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2014.05.004","article-title":"Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging","volume":"158","author":"G Coscas","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"pone.0349947.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0673","article-title":"Efficacy of Intravitreal Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration Patients with or without Polypoidal Choroidal Vasculopathy: A Meta-Analysis","volume":"86","author":"L Wang","year":"2025","journal-title":"Br J Hosp Med (Lond)"},{"issue":"6","key":"pone.0349947.ref017","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s10384-025-01228-w","article-title":"Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis","volume":"69","author":"Y Yanagi","year":"2025","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"pone.0349947.ref018","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaophthalmol.2020.3001","article-title":"Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents","volume":"138","author":"RN Evans","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"pone.0349947.ref019","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","volume":"120","author":"GJ Jaffe","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"pone.0349947.ref020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40123-025-01093-3","article-title":"To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review","volume":"14","author":"AJE Foss","year":"2025","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"pone.0349947.ref021","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/IAE.0000000000003885","article-title":"Predictors of 3-month and 1-year visual outcomes after vitrectomy with subretinal tissue plasminogen activator injection for submacular hemorrhage","volume":"43","author":"M Miki","year":"2023","journal-title":"Retina"},{"issue":"2","key":"pone.0349947.ref022","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s10384-025-01276-2","article-title":"Recurrence associated with 2-year visual acuity after subretinal tissue plasminogen activator for submacular hemorrhage in neovascular age-related macular degeneration","volume":"70","author":"M Tanaka","year":"2026","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"pone.0349947.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271447","article-title":"Visual prognosis of submacular hemorrhage secondary to age-related macular degeneration: A retrospective multicenter survey","volume":"17","author":"N Inoue","year":"2022","journal-title":"PLoS One"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:25:35Z","timestamp":1789147535000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349947"}},"subtitle":[],"editor":[{"given":"Shinji","family":"Kakihara","sequence":"first","affiliation":[{"name":"Shinshu University School of Medicine","place":["JAPAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349947","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}